Skip to main content
. 2022 Sep 2;113(11):3912–3921. doi: 10.1111/cas.15539

FIGURE 2.

FIGURE 2

Kaplan‐Meier plots analysis showing progression‐free survival (A) and overall survival (B) for 396 patients with grade ≥2 immune‐related adverse events (irAEs) and with grade 1 or no irAEs who survived longer than 3 months after propensity score matching